• Source:JND
Add as a preferred

India’s drug regulator has cleared the use of Ozempic (semaglutide) for adults with type-2 diabetes, paving the way for Danish drugmaker Novo Nordisk to launch the medicine in the country. The move is expected to provide access to a treatment that has already transformed diabetes care globally.

The approval from the Central Drugs Standard Control Organisation (CDSCO) comes ahead of the company’s patent expiry in March 2026, a development likely to invite Indian generic makers and lower the cost of treatment.

What is Ozempic?

Ozempic is the trade name for semaglutide, a drug from the class of GLP-1 receptor agonists. It is taken once a week by injection and works by mimicking the natural hormone GLP-1. The drug increases insulin release when blood sugar is high, reduces excess glucagon secretion, slows digestion and in higher doses, suppresses appetite.

ALSO READ: UPSSSC To Start Document Verification For 361 Junior Analyst (Medicine) Posts From October 6

Originally approved by the US FDA in 2017 for type-2 diabetes, Ozempic has since gained global attention for its weight-loss effects. A higher-dose version, marketed as Wegovy, is authorised for obesity management.

Ozempic Benefits And Clinical Impact

Large international studies show that semaglutide improves blood-sugar control and supports weight loss. In patients with diabetes and high cardiovascular risk, it has also reduced the chances of heart attacks and strokes.

For Indian patients, the medicine offers fewer injections compared to daily regimens and could play a role in tackling lifestyle-related conditions such as obesity alongside diabetes.

Ozempic Risks And Concerns

Despite its success, Ozempic is not without side effects. Patients often report nausea, vomiting and stomach discomfort when starting the drug. Long-term use has been linked with nutritional deficiencies and muscle loss.

More serious risks flagged by experts include pancreatitis, gallbladder issues, kidney problems and thyroid-related warnings. Some studies also raise concerns about mood changes, anxiety and a potential cancer risk, requiring close medical supervision.

Ozempic Cost in India

Novo Nordisk has not yet disclosed the Indian price of Ozempic. However, Wegovy, its obesity-specific version, is expected to cost between Rs 17,345 and Rs 26,015 per month depending on the dose and pack size.

Similar drugs such as Mounjaro (tirzepatide) are already available in India, with starter packs priced between Rs 14,000 and Rs 17,500 per month. Market competition, bulk government procurement and future generic launches may eventually reduce costs.

ALSO READ: Indian Pharma Stocks Plummet After Trump's 100% Tariff Announcement On Branded Drugs

Global Popularity and Celebrity Use

Ozempic has also made headlines due to its use among celebrities for weight loss. Elon Musk, Amy Schumer, Sharon Osbourne, Rebel Wilson and Lizzo are among those who have spoken publicly about using semaglutide drugs. While some praised its effectiveness, others admitted to stopping due to side effects such as nausea.

What Patients Should Know

Doctors warn that Ozempic is not suitable for self-administration without medical supervision. It should only be prescribed by specialists who can monitor blood sugar, manage side effects and assess long-term risks.